| A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods R Gosselin, JT Owings, RH White, R Hutchinson, J Branch, K Mahackian, ... Thrombosis and haemostasis 83 (05), 698-703, 2000 | 3286 | 2000 |
| Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism V Pengo, AWA Lensing, MH Prins, A Marchiori, BL Davidson, F Tiozzo, ... New England Journal of Medicine 350 (22), 2257-2264, 2004 | 2489 | 2004 |
| Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) G Palareti, N Leali, S Coccheri, M Poggi, C Manotti, A D'Angelo, V Pengo, ... The Lancet 348 (9025), 423-428, 1996 | 1722 | 1996 |
| Update of the guidelines for lupus anticoagulant detection V Pengo, A Tripodi, G Reber, JH Rand, TL Ortel, M Galli, PG De Groot Journal of Thrombosis and Haemostasis 7 (10), 1737-1740, 2009 | 1477* | 2009 |
| EULAR recommendations for the management of antiphospholipid syndrome in adults MG Tektonidou, L Andreoli, M Limper, Z Amoura, R Cervera, ... Annals of the rheumatic diseases 78 (10), 1296-1304, 2019 | 1128 | 2019 |
| The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective … P Prandoni, F Noventa, A Ghirarduzzi, V Pengo, E Bernardi, R Pesavento, ... Haematologica 92 (2), 199-205, 2007 | 1057 | 2007 |
| D-dimer testing to determine the duration of anticoagulation therapy G Palareti, B Cosmi, C Legnani, A Tosetto, C Brusi, A Iorio, V Pengo, ... New England Journal of Medicine 355 (17), 1780-1789, 2006 | 952 | 2006 |
| Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome V Pengo, G Denas, G Zoppellaro, SP Jose, A Hoxha, A Ruffatti, L Andreoli, ... Blood, The Journal of the American Society of Hematology 132 (13), 1365-1371, 2018 | 831 | 2018 |
| Chronic thromboembolic pulmonary hypertension NH Kim, M Delcroix, DP Jenkins, R Channick, P Dartevelle, P Jansa, ... Journal of the American College of Cardiology 62 (25S), D92-D99, 2013 | 812 | 2013 |
| Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome V Pengo, A Ruffatti, C Legnani, P Gresele, D Barcellona, N Erba, S Testa, ... Journal of thrombosis and haemostasis 8 (2), 237-242, 2010 | 743 | 2010 |
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th … G Ruiz-Irastorza, MJ Cuadrado, I Ruiz-Arruza, R Brey, M Crowther, ... Lupus 20 (2), 206-218, 2011 | 632 | 2011 |
| The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants P Thiagarajan, V Pengo, SS Shapiro Blood 68 (4), 869-874, 1986 | 588 | 1986 |
| PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2 S Dalla-Volta, A Palla, A Santolicandro, C Giuntini, V Pengo, O Visioli, ... Journal of the American College of Cardiology 20 (3), 520-526, 1992 | 563 | 1992 |
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study V Pengo, A Ruffatti, C Legnani, S Testa, T Fierro, F Marongiu, ... Blood, The Journal of the American Society of Hematology 118 (17), 4714-4718, 2011 | 528 | 2011 |
| Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review A Iorio, C Kearon, E Filippucci, M Marcucci, A Macura, V Pengo, ... Archives of internal medicine 170 (19), 1710-1716, 2010 | 496 | 2010 |
| Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African … H Takahashi, GR Wilkinson, EA Nutescu, T Morita, MD Ritchie, ... Pharmacogenetics and genomics 16 (2), 101-110, 2006 | 486 | 2006 |
| Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance MG Scordo, V Pengo, E Spina, ML Dahl, M Gusella, R Padrini Clinical Pharmacology & Therapeutics 72 (6), 702-710, 2002 | 468 | 2002 |
| The 2023 ACR/EULAR antiphospholipid syndrome classification criteria M Barbhaiya, S Zuily, R Naden, A Hendry, F Manneville, MC Amigo, ... Arthritis & Rheumatology 75 (10), 1687-1702, 2023 | 415 | 2023 |
| Antibody profiles for the diagnosis of antiphospholipid syndrome V Pengo, A Biasiolo, C Pegoraro, U Cucchini, F Noventa, S Iliceto Thrombosis and haemostasis 93 (06), 1147-1152, 2005 | 412 | 2005 |
| Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis KMJ Devreese, PG de Groot, B de Laat, D Erkan, EJ Favaloro, I Mackie, ... Journal of thrombosis and haemostasis 18 (11), 2828-2839, 2020 | 372 | 2020 |